Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer
NCT07309289Phase 3Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jul 2025
- Primary completion
- Mar 2029
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of irinotecan liposome injection in metastatic colorectal cancer (mCRC), sponsored by Zhongshan Hospital, Fudan University. Started Jul 2025; status: recruiting.
02
Drugs
irinotecan liposome injection
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT07309289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07309289.